Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 12/20 | 0.59 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.59 |
| ▸ | DRD3 | P35462 | 3/20 | 0.48 |
| ▸ | HTR6 | P50406 | 2/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3759923 | 0.88 | MEN1 (0.46) | DRD2SLC6A4DRD3HTR6 | |
| SCHEMBL3774918 | 0.87 | DRD2 (0.61) | DRD2SLC6A4DRD3PKM | |
| SCHEMBL2783261 | 0.84 | DRD2 (0.58) | DRD2SLC6A4DRD3HTR6PKM | |
| SCHEMBL3772530 | 0.84 | DRD2 (0.58) | DRD2SLC6A4DRD3 | |
| SCHEMBL2784945 | 0.84 | DRD2 (0.58) | DRD2SLC6A4DRD3PKMSIGMAR1 | |
| SCHEMBL3768112 | 0.82 | DRD2 (0.59) | DRD2SLC6A4DRD3HTR6 | |
| SCHEMBL5506480 | 0.82 | DRD2 (0.42) | DRD2SLC6A4DRD3HTR6 | |
| SCHEMBL2781297 | 0.81 | DRD2 (0.54) | DRD2SLC6A4DRD3HTR6 | |
| SCHEMBL2783947 | 0.81 | DRD2 (0.54) | DRD2SLC6A4DRD3HTR6 | |
| SCHEMBL5502404 | 0.81 | DRD2 (0.54) | DRD2SLC6A4DRD3HTR6PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7851629-B2 | Disubstituted phenylpiperidines as modulators of dopamine and serotonin neurotransmission | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2010-12-14 | — | — | US | claimed |
| EP-1768958-B1 | NEW DISUBSTITUTED PHENYLPIPERIDINES AS MODULATORS OF DOPAMINE AND SEROTONIN NEUROTRANSMISSION | NSAB AF NEUROSEARCH SWEDEN AB (DK) | 2009-11-18 | — | — | EP | claimed |
| US-20070179185-A1 | NEW DISUBSTITUTED PHENYLPIPERIDINES AS MODULATORS OF DOPAMINE AND SEROTONIN NEUROTRANSMISSION | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2007-08-02 | — | — | US | claimed |
| EP-1768958-A1 | NEW DISUBSTITUTED PHENYLPIPERIDINES AS MODULATORS OF DOPAMINE AND SEROTONIN NEUROTRANSMISSION | A. CARLSSON RESEARCH AB (SE) | 2007-04-04 | — | — | EP | claimed |
| WO-2005121088-A1 | NEW DISUBSTITUTED PHENYLPIPERIDINES AS MODULATORS OF DOPAMINE AND SEROTONIN NEUROTRANSMISSION | A. CARLSSON RESEARCH AB (SE) | 2005-12-22 | — | — | WO | claimed |
| US-7851629-B2 | Disubstituted phenylpiperidines as modulators of dopamine and serotonin neurotransmission | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2010-12-14 | — | — | US | disclosed |
| EP-1768958-B1 | NEW DISUBSTITUTED PHENYLPIPERIDINES AS MODULATORS OF DOPAMINE AND SEROTONIN NEUROTRANSMISSION | NSAB AF NEUROSEARCH SWEDEN AB (DK) | 2009-11-18 | — | — | EP | disclosed |
| US-20070179185-A1 | NEW DISUBSTITUTED PHENYLPIPERIDINES AS MODULATORS OF DOPAMINE AND SEROTONIN NEUROTRANSMISSION | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2007-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179185-A1 | NEW DISUBSTITUTED PHENYLPIPERIDINES AS MODULATORS OF DOPAMINE AND SEROTONIN NEUROTRANSMISSION | DRD2, DRD4, HTR4 | DRD2 1/4885SLC6A4 21/4885DRD3 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.